Clinical trial
Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's
NCT00322036 · Myrexis Inc., Industry · Terminated
Key facts
| NCT number | NCT00322036 |
|---|---|
| Title | Global Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's |
| Official title | Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment With MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects With Mild Dementia of the Alzheimer's Type |
| Lead sponsor | Myrexis Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Alzheimer Disease, Dementia |
| Intervention type | Drug |
| Interventions | MPC-7869 |
| Enrollment | 800 |
| Start date | May 1, 2006 |
| Completion | Dec 1, 2008 |
| First posted | May 4, 2006 |
| Last update posted | Aug 5, 2008 |
| Countries | Belgium, Canada, Denmark, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: